The estimated Net Worth of William Jl Rieflin is at least $1.84 Million dollars as of 19 November 2020. Mr. Rieflin owns over 10,000 units of Ngm Biopharmaceuticals Inc stock worth over $27,720 and over the last 5 years he sold NGM stock worth over $0. In addition, he makes $1,813,130 as Executive Chairman of the Board of Directors at Ngm Biopharmaceuticals Inc.
William has made over 2 trades of the Ngm Biopharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of NGM stock worth $162,200 on 19 November 2020.
The largest trade he's ever made was buying 10,000 units of Ngm Biopharmaceuticals Inc stock on 19 November 2020 worth over $162,200. On average, William trades about 1,125 units every 24 days since 2019. As of 19 November 2020 he still owns at least 18,000 units of Ngm Biopharmaceuticals Inc stock.
You can see the complete history of Mr. Rieflin stock trades at the bottom of the page.
William J. Rieflin J.D. serves as Executive Chairman of the Board of Directors of the Company. Mr. Rieflin became Executive Chairman of our Board of Directors in September 2018, after having served as our Chief Executive Officer and a member of our Board of Directors since September 2010. From 2004 until 2010, he served as President of XenoPort, Inc., a biotechnology company focused on the discovery and development of transported prodrugs. From 1996 to 2004, he held various positions with Tularik, a biotechnology company focused on the discovery and development of product candidates based on the regulation of gene expression that was acquired by Amgen in 2004, most recently serving as Executive Vice President, Administration, Chief Financial Officer, General Counsel and Secretary. Mr. Rieflin has served as a director at RAPT Therapeutics, Inc., a publicly-traded biotechnology company, since 2015 and Kallyope Inc. since 2016. Mr. Rieflin also served as a director of Flexus Biosciences until its acquisition in 2015, a director of XenoPort until its acquisition in 2016 and as a director of Anacor Pharmaceuticals until its acquisition in 2016. Mr. Rieflin received a B.S. from Cornell University, an M.B.A. from the University of Chicago Graduate School of Business and a J.D. from Stanford Law School.
As the Executive Chairman of the Board of Directors of Ngm Biopharmaceuticals Inc, the total compensation of William Rieflin at Ngm Biopharmaceuticals Inc is $1,813,130. There are 2 executives at Ngm Biopharmaceuticals Inc getting paid more, with David Woodhouse having the highest compensation of $2,092,150.
William Rieflin is 60, he's been the Executive Chairman of the Board of Directors of Ngm Biopharmaceuticals Inc since 2018. There are 3 older and 13 younger executives at Ngm Biopharmaceuticals Inc. The oldest executive at Ngm Biopharmaceuticals Inc is David Goeddel, 68, who is the Lead independent director.
William's mailing address filed with the SEC is C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 6 years, insiders at Ngm Biopharmaceuticals Inc have traded over $9,159,599 worth of Ngm Biopharmaceuticals Inc stock and bought 18,889,291 units worth $177,396,366 . The most active insiders traders include Peter Svennilson, David V Goeddel, and Group L P Svennilson Peter .... On average, Ngm Biopharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of $171,092. The most recent stock trade was executed by Group L Ptcg Opportunity Ii... on 15 November 2023, trading 22,631 units of NGM stock currently worth $15,615.
ngm bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. our initial r&d focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer. ngm bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. as we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. work
Ngm Biopharmaceuticals Inc executives and other stock owners filed with the SEC include: